DIAGNOS Will Utilize its Artificial Intelligence Medical Platform FLAIRE in Response to the “US White House – Call to Action” to Analyse and Transform COVID-19 Data into Clinical Knowledge
Brossard, Quebec, March 25, 2020 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces that it is participating in the “Call to Action” initiative implemented by the White House Office of Science and Technology Policy. DIAGNOS has accessed a significant dataset with the objective of analysing these medical documents with its AI Medical Platform, called FLAIRE, in order to identify key factors that could assist in the battle against the Coronavirus.
In response to the COVID-19 pandemic, the White House and a coalition of leading research groups have prepared the COVID-19 Open Research Dataset (CORD-19). CORD-19 is a resource of over 44,000 scholarly articles, including over 29,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses. This dataset is provided to the global research community to apply recent advances in natural language processing and other AI techniques to generate new insights in support of the ongoing fight against this infectious disease. There is a growing urgency for these approaches because of the rapid acceleration in new coronavirus literature, making it difficult for the medical research community to keep up.
Call to Action (from the White House)The White House is issuing a call to action to the world’s artificial intelligence experts to develop text and data mining tools that can help the medical community develop answers to high priority scientific questions. The CORD-19 dataset represents the most extensive machine-readable coronavirus literature collection available for data mining to date. This allows the worldwide AI research community the opportunity to apply text and data mining approaches to find answers to questions within, and connect insights across, this content in support of the ongoing COVID-19 response efforts worldwide.
Mr. André Larente, CEO of Diagnos stated: “Diagnos AI platform has been built to address the complexity of multiple sources of data that includes text mining, data mining and medical imaging. The proprietary technology has been developed over a number of years in order to identify medical challenges, for example cardio vascular issues have resulted in new tests to address hypertensive patient complications and to predict a potential stroke. The intention of FLAIRE in response to the White House Call to Action is to assist in resolving some of the issues caused by the virus by analyzing the dataset made available by the US authorities.’’
The Standing Committee on Emerging Infectious Disease and 21st Century Health Threats of the US and the WHO identified 10 scientific questions that are vital to address this international crisis. These questions include studying the transmission and incubation of the virus, risk factors for getting the COVID-19, the origin of the virus, and the proper medical practice for treating this disease.
Mr. Francis Bellido, PhD in Medical Microbiology and board member at Diagnos added: “One outcome that is particularly ”remarkable” in the COVID-19 crisis is that the majority of the deceased victims had one or several pre-condition(s) before the infection struck such as hypertension, diabetes, obesity or other Cardio Vascular issues, which are the “sweet spots” for the Diagnos diagnostic assisted platform. We believe that this virus could further alter the cartography of the retina in such patients, and if confirmed, creating the possibility of an additional facet to our existing detection tool for our existing patients.’’Dr. Hadi Chakor, Chief Medical Officer at Diagnos added: ‘’One of the treatments for COVID-19 is the use of chloroquine or hydroxychloroquine. The recommendations of the American Academy of Ophthalmology on the screening of chloroquine (CQ) and hydroxychloroquine (HCQ) are very clear after taking high doses and for a long period of use, a rigorous follow-up with patients is required. These conditions represent the most severe risks of developing morphological alterations in the retina after treatment with chloroquine. Also, previous studies demonstrate clearly that chloroquine disrupts lysosomal function in retinal neurons and RPE. Modern screening should be based on primary AI-based automatic screening tests to assess the fundus plus optical spectral coherence tomography (SD OCT) exams. These investigations should look beyond the central macula to provide objective screening and to detect subtle changes on the retinal membrane.’’The Corporation is also announcing a correction to its press release dated March 9th, 2020: The number of common shares that Mr. Tristram Coffin would hold assuming the exercise of stock warrants should read 11,047,561 instead of 10,624,560.
About DIAGNOSDIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) platform FLAIRE. Diagnos can build application rapidly using the FLAIRE platform such as CARA (Computer Assisted Retina Analysis). CARA is an application that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration, European Union and other countries.Additional information is available at www.diagnos.com and www.sedar.com.This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Pharmaceutical Excipients Market To Reach USD 10.15 Billion By 2027
New York, April 01, 2020 (GLOBE NEWSWIRE) — According to the current analysis of Reports and Data, the global Pharmaceutical Excipients Market valued at USD 6.53 billion in 2019 and is expected to reach USD 10.15 billion by the year 2027, at a CAGR of 5.7%. Excipients are the products that do not show any activity of the drug but facilitates the drug delivery process. The increase in the outbreak of pandemic or epidemic diseases across the globe is the primary factor for boosting the growth of the market. The problems associated with instability, poor solubility, and absorption of active pharmaceutical ingredients are driving the demand for pharmaceutical excipients. The development of nanotechnology for the administration of drugs is further boosting the growth of the market. In 2015, the amount of manufacturing of final products of drugs in Japan accounted for 6,820.4 billion yen, the amount of import was 4,022 billion yen. Increasing outbreak of life threatening diseases and increasing incidences of resistance over traditional treatment plan resulting in increasing number of final production are expected to boost the market growth.
North America has obtained remarkable growth in the market due to the awareness among the consumers for better healthcare, government initiatives for research and development of new drugs, clinical trials, and due to better facilities for healthcare in the region. However, the high cost of drug development is the primary restraint to market growth.Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/2713The COVID-19 Impact: The sudden outbreak of COVID-19 has reported significant growth in the pharmaceutical excipients market. According to the recent epidemiological data the fight against COVID-19 is expected to continue furthermore for some considerable time, especially in Europe. Pharmaceutical companies are engaged in developing the appropriate and desired treatment plan or medicines. Increasing production of final products in the industry has gained huge demand of excipients required for the formulation. However, it might impact negatively to emerging nations in Asia such as China and India, due to the increased restrictions towards international trade i.e., export or import. In such circumstances, companies especially in US and Europe have shifted towards manufacturer from the same state or backward expansion strategies, i.e., companies are owning their own excipients manufacturing plants. For instance, ReForm Biologics, a pharmaceutical technology company and MilliporeSigma have entered an agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. Certain excipients have been established high acceptance for manufacturing drug for COVID-19 treatment for example, hydroxypropyl beta-cyclodextrins (HPβCD) it acts as functional excipient. Certain bodies are also playing vital role in market impact of COVID-19 outbreak. EXCiPACT updated position paper on COVID-19 (Coronavirus) EXCiPACT asbl is a non-profit organisation that require excipient users to qualify their suppliers based on GMP/GDP audits. It regulates such an independent, high quality, third party Certification Scheme available to pharmaceutical excipient manufacturers and distributors worldwide.Further key findings from the report suggestEvonik in the year 2017 had launched a new sterile, and ultra-low-metal content bioresorbable polymers known as RESOMER ZERO it is an ultra-low tin content PLGA poly (lactic-co-glycolic acid) excipient and is the first sterile controlled release (PLGA) excipient in the market. It was designed for the controlled-release parenteral drug formulation.Croda International, in the year 2018 had launched Moonshine Effect Pigments, it is a range of borosilicate-based effect pigments, it is specially designed for personal care products, the quality borosilicate substrate produces the effect exceptional vibrancy, intensity, and color transmission for eye-catching results in cosmetic formulations.JRS Pharma had received an EXCiPACT Certificate from DQS for the production of Microcrystalline Cellulose and Silicified Microcrystalline Cellulose and for Good Distribution Practice for the central logistic warehouse. The certificate justifies that the Micro cellulose is manufactured and distributed according to the EXCiPACT Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certification Standard. The certificate is beneficial for the drug manufacturers to reduce their efforts and costs for performing quality control.Oral formulations in the formulations segment have obtained the largest share due to the rise in demand for formulations like tablets, capsules, and oral solutions and suspensions. It is likely to grow with a CAGR of 5.9% in the forecast period.Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), Croda International (UK). Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France) are the key players in the Pharmaceutical Excipients marketBUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/2713For this purpose, Reports and Data have segmented the Pharmaceutical Excipients market on the basis of products, functionality, formulations, end use, and region. Products Outlook (Revenue in Million USD; (2017–2027)Organic ChemicalsOleochemicalsFatty AlcoholsMineral StearatesGlycerinOther OleochemicalsCarbohydratesSugarsActual SugarsLactoseSucroseDextrose (D-Glucose)Sugar AlcoholsMannitolSorbitolOther Sugar AlcoholsArtificial SweetenersCelluloseMicrocrystalline CelluloseCellulose EthersCMC and Croscarmellose SodiumCellulose EstersStarchModified StarchDried StarchConverted StarchPetrochemicalsGlycolsPolyethylene GlycolPropylene GlycolPovidonesMineral HydrocarbonsPetrolatumMineral WaxesMineral OilsAcrylic PolymersOther PetrochemicalsProteinsOther Organic ChemicalsInorganic ChemicalsCalcium PhosphateMetal OxidesHalitesCalcium CarbonateCalcium SulfateOther Inorganic ChemicalsOthersPharmaceutical-Grade Water MucilageFunctionality Outlook (Revenue in Million USD; (2017–2027)Fillers and DiluentsSuspending and Viscosity AgentsCoating AgentsBindersFlavouring Agents and SweetenersDisintegratesColorantsLubricants and GlidantsPreservativesEmulsifying AgentsOthersFormulations Outlook (Revenue in Million USD; (2017–2027)Oral FormulationsTabletsCapsulesHard Gelatin CapsulesSoft Gelatin CapsulesLiquid FormulationsTopical FormulationsParenteral FormulationsOthersEnd Use Outlook (Revenue in Million USD; (2017–2027)Pharmaceutical companiesChemical companiesOthersRegional Outlook (Revenue in Million USD; (2017–2027)North AmericaU.SCanadaEuropeGermanyFranceUKSpainItalyRest of the EuropeAsia PacificChinaIndiaJapanRest of Asia-PacificMiddle East & AfricaLatin AmericaBrazilTo identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/pharmaceutical-excipients-marketAbout Reports and DataReports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: firstname.lastname@example.org
OMNIQ’s CEO Interviewed on “CEO Roadshow”
SALT LAKE CITY, April 01, 2020 (GLOBE NEWSWIRE) — OMNIQ Corp. (OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, today announced that its CEO, Shai Lustgarten, recently conducted an interview with Mike Elliott of CEO Roadshow.
The interview may be viewed in its entirety via: CEORoadshowhttp://ceoroadshow.com/ceoroadshow-interview-with-shai-lustgarten-president-ceo-of-omniq-corp-omqs/Interview Highlights:OMNIQ provides unique and scalable AI-Machine Vision technology solutions to the Public Safety, Supply Chain and Automated parking industriesCompany customer base comprised of Fortune 500 leading companies, governments, municipalities, schools and colleges, cultural and religious centers and others.Company participates in rapidly growing, multi-billion dollar market verticalsOMNIQ holds 8 patents and has developed algorithms applicable to:
– Vehicle comprehensive license plate, color and make recognition for use in homeland security, public safety and automated parking
– AI-based Machine Vision solutions for supply chain & logistics promoting efficiencies from warehouse/yard management through point of sale
– Comprehensive parking management solution enabling ticketless parking, automation and revenue control currently installed at more than 30 major airports in the U.S.Company in a unique position offering state-of-the-art, high margin technology solutionsAbout OMNIQ, Corp.
OMNIQ Corp. (OMQS) provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments.
OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad.
The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate”, “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products particularly during the current health crisis , the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at http://www.sec.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.Investor Contact:
John Nesbett/Jen Belodeau
IMS Investor Relations
Enterprise Connect Announces Winners for the Best of Enterprise Connect Industry Awards
SAN FRANCISCO, April 01, 2020 (GLOBE NEWSWIRE) — Enterprise Connect, the leading conference and exhibition for enterprise communications and collaboration, is pleased to announce the winners for The Best of Enterprise Connect awards program. Best of Enterprise Connect recognizes excellence and innovation in the enterprise communications and collaboration industry.
“We’d like to extend a congratulations to all of this year’s Best of Enterprise Connect winners and participants,” said Eric Krapf, Enterprise Connect General Manager and Program Co-Chair. “These companies represent the most innovative technologies that are making a significant impact on the enterprise communications and collaboration industry.”Recipients of The Best of Enterprise Connect Awards include:OVERALL Best of Enterprise Connect (Winner)JourneyJourney Identity Platform, which aims to make it easy for enterprises to establish trusted interactions with their customers that simultaneously solve for security, customer experience and privacy using an encrypted network and a platform of best-in-class identity solutions that can be dynamically applied using the enterprise’s existing mobile app.OVERALL Best of Enterprise Connect (Finalists)Genesys Predictive Engagement, now working within Genesys Cloud, new capabilities enable businesses to anticipate individual customer needs, building on every interaction across multiple channels and events to improve and personalize future engagements.Glia Conversational Compliance AI Framework, part of Glia’s digital-first customer service platform, provides the framework to provision, measure and manage AI-driven virtual assistants to converse with customers and operator assistants to guide agents.Mio’s new intercompany federation for Microsoft Teams, Slack and Cisco WebEx Teams enables users to chat seamlessly with external business contacts who use a different messaging app.Omilia Natural Language Solutions — Omilia Cloud Platform miniApps, zero-touch natural language microservices that handle a single dialog task; instantly deployable to any call center provider and seamlessly adapted to any CCaaS service creation environmentPexip, Adaptive Composition, an AI-powered technology with real-time face detection, auto-framing, and optimized use of screen real estate; works with any camera-enabled deviceBest Innovation for Meeting Rooms (Three-way tie)AvayaAvaya Spaces, a simple cloud solution that integrates friction-free web meetings and team collaboration into one app.Kramer ElectronicsVIA GO², which gives iOS, Android, Chromebook, PC and Mac users instant wireless connectivity with advanced presentation technology, featuring content streaming for 4K mirrored images and video playback.RingCentralFor a new product that will be announced at Enterprise Connect.Best Innovation in Customer ExperienceJourneyJourney Identity Platform, which aims to make it easy for enterprises to establish trusted interactions with their customers that simultaneously solve for security, customer experience and privacy using an encrypted network and a platform of best-in-class identity solutions that can be dynamically applied using the enterprise’s existing mobile app.Best Application of Artificial Intelligence (Three-way tie)GenesysGenesys Predictive Engagement, now working within Genesys Cloud, new capabilities enable businesses to anticipate individual customer needs, building on every interaction across multiple channels and events to improve and personalize future engagements.PexipAdaptive Composition, an AI-powered technology with real-time face detection, auto-framing and optimized use of screen real estate; works with any camera-enabled device.Theta LakeCompliant Collaboration Archive, new module within Theta Lake’s Compliance Suite for record keeping, archiving and eDiscovery requirements for video, audio and collaboration chat, with on-demand compliance risk analysis using AI and ML across leading UCaaS platforms (RingCentral, WebEx, Microsoft Teams, Zoom, LogMeIn, Red Box).Best Innovation for Advancing Employee/End User EngagementEmbrava (Winner)Embrava Desk Sign, a smart sensor IoT device designed for Hot Desking, Office Hoteling and Activity-Based Working.Mio (Runner-up)Mio’s new intercompany federation for Microsoft Teams, Slack and WebEx Teams, enables users to seamlessly chat with their external business contacts who use a different messaging app.Best of Enterprise Connect judges for 2020 included: Jon Arnold, principal, J Arnold & Associates; Brent Kelly, president & principal analyst, KelCor; Steve Leaden, president, Leaden Associates and Sheila McGee-Smith, founder & principal analyst, McGee-Smith Analytics.Enterprise Connect 2020 will take place August 3rd– 6th at the Moscone Center in San Francisco. For more information on #E20 and to register for the event, go to www.enterpriseconnect.com/sanfrancisco.About Enterprise Connect
For 30 years, Enterprise Connect has been the leading conference and exhibition for enterprise Unified Communications and Collaboration in North America. Enterprise Connect brings corporate IT decision makers together with the industry’s vendors, analysts and consultants to focus on the issues central to enterprise networks and communications. Enterprise Connect owns and produces No Jitter, (nojitter.com), providing daily blogging and analysis of enterprise communications, and it also serves the community with a weekly email newsletter, research surveys and a Webinar Series. For more information, visit enterpriseconnect.com/sanfrancisco. Enterprise Connect is brought to you by Informa Tech.About Informa Tech
Informa Tech is a market leading provider of integrated research, media, training and events to the global Technology community. We’re an international business of more than 600 colleagues, operating in more than 20 markets. Our aim is to inspire the Technology community to design, build and run a better digital world through research, media, training and event brands that inform, educate and connect. Over 7,000 professionals subscribe to our research, with 225,000 delegates attending our events and over 18,000 students participating in our training programs each year, and nearly 4 million people visiting our digital communities each month. Learn more about Informa Tech.Media Contact:
Latest News9 months ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence11 months ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence12 months ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence10 months ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence12 months ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence12 months ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence10 months ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence6 months ago
Mogo announces a digital lending pilot with goeasy Ltd.